Preclinical News and Research

RSS

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Biocryst reports financial results for first quarter 2013

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013.

7 May 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

6 May 2013

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

5 May 2013

Researchers issue statement regarding use of unproven stem cell therapies

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

4 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease.

2 May 2013

Scientists pursue new therapies as H7N9 flu spreads in China

An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1.

2 May 2013

Targeted therapy prevents rare neurodevelopmental disorder seizures

Rapamycin treatment reduces seizure frequency and improves receptive language in patients with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, or Pretzel syndrome, a study finds.

29 Apr 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.

26 Apr 2013

Preclinical News and Research

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Rigel reports net loss of $25.6 million in first quarter 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Biocryst reports financial results for first quarter 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

Researchers issue statement regarding use of unproven stem cell therapies

Regeneron Pharmaceuticals expands ophthalmology portfolio

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Scientists pursue new therapies as H7N9 flu spreads in China

Targeted therapy prevents rare neurodevelopmental disorder seizures

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Opsona raises €33M in oversubscribed financing round

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics